Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial

A standard objective in the management of T2D is the achievement and maintenance of HbA1C targets, but the duration of time that patients spend within glycemic control targets has not been previously reported for oral semaglutide (sema). In this exploratory analysis, the duration of time that patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian journal of endocrinology and metabolism 2022-03, Vol.26 (Suppl 1), p.S17-S18
Hauptverfasser: Prakash, Prashanth S, Rosenstock, Julio, Cariou, Bertrand, Christiansen, Erik, Hertz, Christin l, Montanya, Eduard, Nielsen, Morten Abildlund, Knop, Filip K
Format: Artikel
Sprache:eng
Schlagworte:
Abstracts … Esicon 2021
Analysis
Clinical trials
Diabetes therapy
Glycosylated hemoglobin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A standard objective in the management of T2D is the achievement and maintenance of HbA1C targets, but the duration of time that patients spend within glycemic control targets has not been previously reported for oral semaglutide (sema). In this exploratory analysis, the duration of time that patients were in glycemic control (HbA1C
ISSN:2230-9500
2230-8210
2230-8210
2230-9500
DOI:10.4103/2230-8210.342148